Shin Nippon Biomedical Laboratories, Ltd. (2395.T) JPX

1,582.00

+15(+0.96%)

Updated at October 20 12:44PM

Currency In JPY

Shin Nippon Biomedical Laboratories, Ltd.

Address

St. Luke’s Tower

Tokyo, 104-0044

Japan

Phone

81 3 5565 5001

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

1457

First IPO Date

March 08, 2004

Key Executives

NameTitlePayYear Born
Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.President, Chairman, Chief Executive Officer, Group Chief Financial Officer, Fisheries Business Officer & Chief Health Officer144.06M1958
Satoshi MatsumotoManaging Executive Officer & GM of Fisheries Division01968
Toshiyuki IwataManaging Executive Officer, R/PR Division Manager & Sustainability Officer0N/A
Shinji NitandaSenior MD of Corporate Development & Corporate Tax Administration and Director01968
Dr. Shu-Ichi Kanazashi M.D., Ph.D.Managing Executive Officer, CMO and General Manager of TR Business Division01960
Mr. Ken Takanashi CPA, MBA.Executive Vice President of Group Corporate Management & Global Business & Director01964
Dr. Hideshi Tsusaki DVM Ph.D.Senior MD, President of Non-Clinical & Global Business Development and Director01967
Kyomi NagatoshiSenior Managing Executive Officer, Head of General Affairs & Human Resources and Director0N/A
Terumasa HiraiManaging Executive Officer & President and Representative Director of SNBL Ina Research Center0N/A
Fumihiko MakinoSenior Executive Officer, Financial Controller and GM of Finance & Accounting0N/A

Description

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.